Annabel O'c Strife

Title: Annabel O'c Strife: Innovator in Cancer Research

Introduction

Annabel O'c Strife is a prominent inventor based in New York, NY (US). She has made significant contributions to the field of cancer research, particularly in understanding chronic myelogenous leukemia (CML). Her work has implications for the development of targeted therapies for this type of cancer.

Latest Patents

Annabel O'c Strife holds a patent related to a human gene/protein involved in chronic myelogenous leukemia. The patent describes the chimeric p120^bcr-abl protein, which exhibits elevated protein tyrosine kinase activity compared to the normal c-abl tyrosine kinase. Hematopoietic progenitors isolated from CML patients in the chronic phase contain a constitutively tyrosine phosphorylated protein that migrates at approximately 62 kDa by SDS-PAGE. This protein, known as p62^dok (p62 protein downstream of tyrosine kinases), was isolated from a hematopoietic cell line expressing p120^bcr-abl. The association of p62^dok with GAP correlates with its tyrosine phosphorylation, indicating its role in a signal transduction pathway downstream of receptor tyrosine kinases.

Career Highlights

Throughout her career, Annabel has worked at esteemed institutions such as Cold Spring Harbor Laboratory and the Sloan-Kettering Institute for Cancer Research. Her research has focused on the molecular mechanisms underlying CML, contributing to a better understanding of the disease and potential therapeutic targets.

Collaborations

Annabel has collaborated with notable colleagues, including Nicholas A Carpino and Ryuji Kobayashi. These collaborations have further advanced the research in the field of cancer biology.

Conclusion

Annabel O'c Strife's innovative work in cancer research, particularly her patent related to chronic myelogenous leukemia, highlights her significant contributions to the scientific community. Her research continues to pave the way for advancements in cancer treatment and understanding.